Healthcare - Biotechnology - NASDAQ - US
$ 15.66
-5.49 %
$ 26 M
Market Cap
-2.33
P/E
CASH FLOW STATEMENT
-3.53 M
OPERATING CASH FLOW
-3.25 K
INVESTING CASH FLOW
11.9 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Cadrenal Therapeutics, Inc. Common Stock
| Net Income | -8.36 M |
| Depreciation & Amortization | 1.98 K |
| Capital Expenditures | -3.25 K |
| Stock-Based Compensation | 710 K |
| Change in Working Capital | 144 K |
| Others | 4.35 M |
| Free Cash Flow | -3.53 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | |
|---|---|---|
| OPERATING CASH FLOW | ||
| Net Income | (8.4) | (6.7) |
| Depreciation & Amortization | 1.98 K | 1.27 K |
| Deferred Income Tax | 0 | 0 |
| Stock Based Compensation | 0.7 | 0 |
| Other Operating Activities | 4.0 | 4.5 |
| Change in Working Capital | 0.1 | 0.6 |
| Cash From Operations | (3.5) | (1.2) |
| INVESTING CASH FLOW | ||
| Capital Expenditures | 3.25 K | 0 |
| Other Items | 0 | 2.28 K |
| Cash From Investing Activities | 3.25 K | 2.28 K |
| FINANCING CASH FLOW | ||
| Common Stock Repurchased | 0 | 0 |
| Total Debt Repaid | (0.2) | 0 |
| Dividends Paid | 0 | 0 |
| Other Financing Activities | 0.2 | 0 |
| Cash From Financing Activities | 11.9 | 1.2 |
| CHANGE IN CASH | ||
| Net Change In Cash | 8.4 | 32.6 K |
| FREE CASH FLOW | ||
| Free Cash Flow | (3.5) | (1.2) |